• 1
    Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677686.
  • 2
    Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333:11181127.
  • 3
    Farrell GC. Drug-induced acute hepatitis. In: FarrellGC, ed. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994:247299.
  • 4
    Zimmerman HJ. Hepatic injury from the treatment of infectious and parasitic diseases. In: ZimmermanHJ, ed. Hepatotoxicity. Philadelphia: Lippincott Williams & Wilkins, 1999:589637.
  • 5
    Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976; 84:181192.
  • 6
    Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a US public health service cooperative surveillance study. Am Rev Respir Dis 1978; 117:9911001.
  • 7
    Grönhagen-Riska C, Hellstrom PE, Fröseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118:461466.
  • 8
    Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6:295298.
  • 9
    Parthasarathy R, Sarma GR, Janardhanam B, Ramachandran P, Santha T, Sivasubramanian S, Somasundaram PR, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986; 67:99108.
  • 10
    Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, Tsai YT, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98:502504.
  • 11
    Thompson NP, Hamilton CMI, Gillespie SH, Clarke SW, Burroughs AK, Mclntyre N. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8:13841388.
  • 12
    Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51:132136.
  • 13
    Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CJ, Lin TP, Lee SD. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997; 12:8791.
  • 14
    Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31:201206.
  • 15
    Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor of antituberculosis drug-induced hepatitis. Hepatology 2002; 35:883889.
  • 16
    Parrish AG, Robson SC, Trey C, Kirsch RE. Retrospective survey of drug-induced liver disease at Groot Schuur Hospital, Cape Town—1983–1987. S Afr Med J 1990; 77:199202.
  • 17
    Acharya SK, Dasarathy S, Kumer TL, Sushma S, Uma Prasanna KS, Tandon A, Sreenivas V, et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996; 23:14481455.
  • 18
    Ryan DE, Ramanathan L, Iida S, Thomas PE, Haniu M, Shively JE, Lieber CS, et al. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Biol Chem 1985; 260:63856393.
  • 19
    Guengerich FP, Shimada T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res 1998; 400:201213.
  • 20
    Maezawa Y, Yamauchi M, Toda G. Association between restriction fragment length polymorphism of the human cytochrome p450IIE1 gene and susceptibility to alcoholic liver cirrhosis. Am J Gastroenterol 1994; 89:561565.
  • 21
    Tsutsumi M, Takada A, Wang JS. Genetic polymorphism of cytochrome P-450 2E1 related to the development of alcoholic liver disease. Gastroenterology 1994; 107:14301435.
  • 22
    Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995; 109:12661273.
  • 23
    Watkins PB. The role of cytochrome P450s in drug-induced liver disease. In: KaplowitzN, DeleveLD, eds. Drug-Induced Liver Disease. New York: Marcel Dekker, 2003:1533.
  • 24
    Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, Bell DA. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994; 4:185192.
  • 25
    American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149:13591374.
  • 26
    Bénichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11:272276.
  • 27
    Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:13231330.
  • 28
    National Tuberculosis Association of the USA. Diagnostic standards and classification of tuberculosis. New York: National Tuberculosis Association, 1961.
  • 29
    Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14:16891692.
  • 30
    Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994; 47:15031508.
  • 31
    Lucas D, Ménez C, Girre C, Berthou F, Bodénez P, Joannet I, Hispard E, et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 1995; 5:298304.
  • 32
    Oneta CM, Lieber CS, Li JJ, Rüttimann S, Schmid B, Lattmann J, Rosman AS, et al. Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J Hepatol 2002; 36:4752.
  • 33
    Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992; 48:361372.
  • 34
    Watanabe J, Hayashi S, Kawajiri K. Different regulations and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′ flanking region. J Biochem 1994; 116:321326.
  • 35
    Powell H, Kitteringham NR, Pirmohamed M, Smith DA, Park BK. Expression of cytochrome P-4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics 1998; 8:411421.
  • 36
    Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphism in the 5′-flanking region change transcriptional regulation of the human cytochrome P-450 II E1 gene. J Biochem 1991; 110:559565.
  • 37
    Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP, Wright JM. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993; 54:142149.
  • 38
    Sarich TC, Adams SP, Petricca G, Wright JM. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J Pharmacol Exp Ther 1999; 289:695702.
  • 39
    Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001; 45:382392.
  • 40
    Park KS, Sohn DH, Veech RL, Song BJ. Translational activation of ethanol-inducible cytochrome P450 (CYP2E1) by isoniazid. Eur J Pharmacol 1993; 248:714.
  • 41
    Ryan DE, Ramanathan L, Iida S, Thomas PE, Haniu M, Shively JE, Lieber CS, et al. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Biol Chem 1985; 260:63856393.